Objective: The present formulation was developed with the intention to formulate versatile 5-fluorouracil (5-FU) mucoadhesive tablet that fulfill the therapeutic need that is lacking in current cancer treatment and aimed at minimizing toxic effect, enhancing efficacy and increasing patient compliance. Method: Mucoadhesive tablets of 5-fluorouracil were prepared by direct compression technique using different grades of polymer with varying concentration. The tablets were compressed using 10 mm flat faced punch on a single stroke-punching machine. The formulations were tested for drug content, hardness, friability, weight variation, thickness, swelling studies, in vitro drug release, ex vivo permeation studies, mucoadhesive strength. Result and Discussion: The formulated mucoadhesive buccal tablet was evaluated for various parameter and formulation F7 was found as the optimum batch. Conclusion: From the above study it was concluded that Formulation F7 was found optimized formulation showing optimum results for all the evaluated parameters. The drug content was 98.75%, swelling index 130 at 6 hours, Mucoadhesive Strength 22.1 and force (N) 0.216801, Residence time was more than 8hours and drug release was found to be 96.78%.
Introductions
Cancer is a disease involving all organs, races, ages, and sex of humans. Among all types of cancer, Oropharyngeal cancer, colorectal cancer contributes to the world most burden and cervical cancer accounts for little extent. Oropharyngeal cancer develops in the part of the throat just behind the mouth called the oropharynx. Oropharynx includes the base of the tongue, soft palate, tonsils, tonsillar pillars and the back wall of the throat [1] . Cervical cancer involving the cervix that is narrow and lowers part of the uterus. About 90% of Oropharyngeal and cervical cancers are squamous cells carcinoma that begins in the epithelial lining in mouth and vagina. Whereas in colorectal cancer columnar cells are affected. Surgery, radiation therapy and chemotherapy are the most common therapies for treating cancer [2] . 5-FU is the drug of choice in oropharyngeal cancer, colorectal cancer, stomach cancer, and cervical cancer. Chemically, 5-FU is a dipodic acid and highly polar in nature with pka values of 8.0 and 13.0. After oral administration, 5-FU is poorly absorbed with erratic variation in bioavailability ranging between 0 to 80%. 5-FU after parenteral administration it is rapidly eliminated with the apparent terminal half-life of approximately 8-20 min [3] . On intravenous administration 5-FU produces severe systemic toxic effects including gastrointestinal, hematological, neural, cardiac and dermatological origin. These problems make 5-FU suitable candidate for Transbuccal/vaginal and rectal delivery. Polymeric drug delivery systems are mainly designed for the efficient delivery of the active drug. Among various polymeric drug delivery systems, interpolyelectrolyte complexes are the newest, efficient form of polymeric carriers for novel drug delivery systems. Carbopol 934, HPMC (K4M and K15 M), Xanthan gum and Gaur gum has established its potential in drug delivery and have been most efficient. Most publications on 5-FU focused only on a single drug delivery system like buccal gels, cervical patches, colorectal drug delivery. Hardly any articles reported on permeation studies and histological effects of 5-FU. A literature review revealed that there is no single drug delivery system available that can be given either through buccal, vaginal or rectal route. The prime goal has to design 5-FU multipurpose tablets with greater efficacy, potency, adaptability to need, minimal toxic effects and better patient compliance than the established marketed product [4, 5] .
Materials and Methods
Materials 5-fluorouracil (5-FU), polyvinyl alcohol, talc, and sodium deoxycholate was procured from ozone international, Mumbai. Carbopol 974p, polyvinylpyrrolidone K30 was procured from Wockhardt Ltd, Aurangabad. Microcrystalline cellulose was procured from RanQ remedies Pvt. Ltd., Pune. All other ingredients were used for laboratory scale.
Methods
Formulation and preparation of mucoadhesive buccal tablets of 5-FU Mucoadhesive tablets 5-fluorouracil (5-FU) were prepared by direct compression technique using different grades of polymer with varying concentration. All the ingredients except magnesium stearate were blended in glass mortar uniformly. After the sufficient mixing of the drug as well as other components, magnesium stearate was added and further mixed for additional 2-3 minutes. The tablets were compressed using 10 mm flat faced punch on a single strokepunching machine. The compositions of all formulation are given in Table 1 . Uniformity of tablet thickness A digital Vernier caliper was used for measurement of the thickness of 10 tablets from each batch, and the results were presented as the mean (± standard deviation [SD]) of 10 measurements.
Friability test
Ten tablets were previously weighed, transferred to the drum of the friabilator (Pharma Test, Hainburg, Germany), rotated at 25 rpm for 4 min and finally reweighed. The percentage loss in weights was calculated and taken as a measure of friability [6] .
Uniformity weight of the tablet
Twenty tablets were selected at random from each batch, weighed individually, and the average weight was calculated.
The batch passes the test for uniformity of weight if not more than two of the individual tablet weight deviates from the average weight by more than the 7.5% as shown in table 3. 
Surface pH
The surface pH of the formulation was determined in order to investigate their possible side effects in vivo. An acidic or alkaline formulation will cause irritation of the mucosal membrane and hence this is an important parameter in developing a mucoadhesive dosage form. A combined glass electrode was used for determination of surface pH. pH was measured at time intervals of 15, 30, 60, 90 and 120 min. The discs were first allowed to swell by keeping them in contact with 5 ml phosphate buffer pH 6.8 for two hours in 50 ml beakers. pH was then noted by bringing the electrode near the surface of the formulation and allowing equilibrating for 1 min. The experiments were carried out in triplicate [7] .
Drug Content uniformity
In this test, 10 tablets were used where each tablet was mashed and transferred into 100 mL volumetric flask. The flasks were brought to the volume by phosphate buffer pH 6.8. Each flask was sonicated using Sonix IV SS-Series (Sonix IV Ultrasonic Cleaning Systems, North Charleston, SC, USA) till dissolution occurred. Then 1 mL of the solution was filtered, suitably diluted, and the final absorbance of the solution was measured at 266 nm using a UV spectrophotometer (V-530; Jasco, Tokyo, Japan) against phosphate buffer (pH 6.8) as a blank [8] .
Swelling study
The tablets were weighed and transferred individually into Petri dishes filled with 20 mL of phosphate buffer (pH 6.8), and the study was conducted for 10 h. Then the tablets were removed from the Petri dishes and excess water was wiped off by a filter paper. The test was done in triplicate. The swelling index was calculated by applying the following equation:
Where W1 is the buccal tablet weight before being dipped into the Petri dish and W2 is the buccal tablet weight after being dipped and wiped [9] .
Ex vivo Mucoadhesive strength (g)
A modified physical balance method was used for determining the ex vivo buccoadhesive strength [13, 14] . Fresh sheep buccal mucosa was obtained from a local slaughterhouse and used within 2 h of slaughter. The mucosal membrane was separated by removing underlying fat and loose tissues. The membrane was washed with distilled water and then with phosphate buffer pH 6.8 and two sides of the balance were made equal before the study. The sheep buccal mucosa was cut into pieces and washed with phosphate buffer pH 6.8. A piece of buccal mucosa was tied to the glass vial, which was filled with phosphate buffer. The glass vial was tightly fitted into a glass beaker (filled with phosphate buffer pH 6.8 at 37°C+1 °C) so that it just touched the mucosal surface. The buccal tablet was stuck to the lower side of a rubber stopper with cyanoacrylate adhesive and adds weight on the right hand pan. A weight of 5 g was removed from the right-hand pan, which lowered the pan along with the tablet over the mucosa. The balance was kept in this position for 5 minutes contact time. The water (equivalent to weight) was added slowly with an infusion set (100 drops/min). To the right-hand pan until the tablet detached from the mucosal surface. This detachment force gave the mucoadhesive strength of then buccal tablet in grams.
Force of adhesion (N) = (Bioadhesive strength (g) ×9.8)/1000
Bond strength (Nm -2 ) =Force of adhesion / surface area [10, 11] .
In vitro release Studies
In order to carry out In-vitro release studies dissolution test apparatus type II (USP) rotating paddle method was used. The studies were carried out for all formulation combination in triplicate, using 900 ml (37 °C, 100 rpm) of isotonic phosphate buffer (pH 6.8) as the dissolution medium. An aliquot of 5ml sample was withdrawn at 0.5, 1, 2, 3, 4,5,6,7 and 8 hours intervals and similar volume was replaced with fresh phosphate buffer (pH 6.8) maintained at the same temperature. The drug content was analyzed spectrophotometrically at 261.4 nm using a UV spectrophotometer (Shimadzu 1601). Each measurement was carried out in triplicate and the average drug content was calculated [12] .
Ex vivo residence time
The Ex vivo residence time was determined using a modified USP dissolution apparatus. The phosphate buffer of pH 6.6 is used as dissolution medium which is maintained at 37C± 2̊ C. A segment of porcine buccal mucosa each of 4 cm length was glued to the surface of glass slide which was then vertically attached to the apparatus. Three tablets of each formulation were hydrated using 15μl pH 6.6 buffer on one side and the hydrated surface was brought into contact with the mucosal membrane. The tablets secured on the glass slide were completely immersed in the buffer solution. The paddle of the dissolution apparatus as adjusted at a distance of 5 cm from the tablet and rotated at 25 rpm the time for complete erosion or detachment from the mucosa was recorded [13] .
Evaluation of mucoadhesive buccal tablet
All the prepared mucoadhesive buccal tablets were evaluated for following official parameter: 1) Hardness 2) Thickness 3) Weight variation 4) Content uniformity 5) Percentage friability The details of the evaluated parameters are shown in table 4. Weight variation data for all the formulations batches indicated no significant difference in the weight of individuals tablets from the average value and weight variation were found to be within IP limits. The average weight all batches F1-F9 were in the range of 226 to 233 mg and with standard deviation within ± 9.94 showed good uniformity in batches. The thickness of all batches F1-F9 (except batch E3 and E4) were in the range of 1.67 to 1.81 mm with standard deviation within ± 0.01 to ± 0.087 showed good uniformity in batches. Batches F3 and F4 showed a thickness of 2.20 mm ± 0.015 and 2.50 ± 0.058 respectively. The hardness values were found to be in the range of 5 to 7 kg/cm 2 . The friability values were found to be within IP limits. The drug content was found to be within the range of 96.02-103.34%.
In-vitro swelling study of mucoadhesive buccal tablets
The swelling percentage of formulated tablets was determined by measuring increased weight after a specific time interval. The results are shown in table 5 and a graphical representation of it is shown in. figure no.1. The result of swelling study indicates that all batches shown good swelling index, appropriate swelling is an essential parameter for uniform and prolonged drug release. The formulation F3 containing HPMC K15 M: CP 934 as 1:2 shows maximum swelling index. Guar gum at 35% w/w concentration shows higher swelling than Xanthan gum at the same concentration.
Surface pH determination of mucoadhesive buccal tablets
The surface pH of the tablets was determined in order to investigate the possibility of any side effects, on the oral cavity. The surface pH was measured by means of a pH paper placed on the surface of the swollen tablets. Tablets from all batches had shown a surface pH in the range of 5 to 7.
In -vitro Mucoadhesive Study
The force required for the detachment of mucoadhesive tablets was measured in gm. The weight is then converted into a force of adhesion measured in Newton.
The results obtained are shown in table 6 and the graphical representation of it is shown in fig no 2. The maximum mucoadhesive strength was obtained for formulation E3 containing HPMC K 15M: CP 934 as 1:2. Xanthan gum and Guar gum at 40% w/w concentration in batch E9 and E10 does not show a significant difference in mucoadhesive strength.
In -vitro residence time
Residence time is an important factor which correlates bioadhesion time of dosage form to the buccal mucosa. The study was carried out for 8 hrs using modified disintegration apparatus. The time for which tablets remain adhered to buccal mucosa shown in table no.8.5. From all the batches Batch F7 was taken for kinetic study as it showed good results for all the evaluation parameters. From kinetic study and R 2 it was concluded that best fit model was Matrix, R 2 was 0.9974.
Conclusion
From the above study it was concluded that Formulation F7 was found optimized formulation showing optimum results for all the evaluated parameters. The drug content was 98.75%, swelling index 130 at 6hours, Mucoadhesive Strength 22.1 and force (N) 0.216801, Residence time was more than 8hours and drug release was found to be 96.78%.
